MARKET

ANEB

ANEB

Anebulo Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.12
-0.00
-0.07%
Closed 16:00 07/29 EDT
OPEN
7.31
PREV CLOSE
7.12
HIGH
7.31
LOW
7.11
VOLUME
1.20K
TURNOVER
--
52 WEEK HIGH
9.33
52 WEEK LOW
6.31
MARKET CAP
166.21M
P/E (TTM)
-949.3333
1D
5D
1M
3M
1Y
5Y
The Danger of Synthetic Cannabinoids
A problem of increasing social importance is the rise in the use of synthetic cannabis alternatives, commonly called K2 or Spice or a number of other brand names. In 2020, 2.4% of high school seniors tried synthetic cannabis.
Benzinga · 3d ago
The Dark Side of Cannabis Legalization and one Biotech Company's Solution
Photo credits: Tim Foster As of July 2021, 18 states have legalized recreational marijuana while another 18 have legalized cannabis solely for medical purposes. Meanwhile, Florida, Connecticut and Hawaii all have introduced legislation supporting legalizat...
Benzinga · 07/12 12:22
Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials
Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) released its third-quarter fiscal 2021 financial results on Tuesday with a net loss of $555,832 or $0.04 per share. 
Benzinga · 06/22 14:27
BRIEF-Anebulo Pharmaceuticals Says On Track To Commence Phase 2 Proof-Of-Concept Clinical Trial With Aneb-001 In Q4
reuters.com · 06/21 20:13
Anebulo Pharmaceuticals Q3 2021 Total Expenses ~$552K; EPS $(0.04)
Third Quarter Financial Results Operating expenses totaled $552,131 in the third quarter of fiscal 2021. The Company did not have any operations in the comparable prior-year period. Net loss
Benzinga · 06/21 20:11
Anebulo Pharmaceuticals reports FQ3 results
Anebulo Pharmaceuticals (ANEB): FQ3 GAAP EPS of -$0.69.Cash and cash equivalents were $3.3M as of March 31, 2021.Press Release
Seekingalpha · 06/21 20:08
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Benzinga · 05/31 15:06
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
 
Benzinga · 05/25 14:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANEB. Analyze the recent business situations of Anebulo Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANEB stock price target is 15.00 with a high estimate of 15.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 23.34M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing solutions for people suffering from cannabinoid overdose and substance addiction. The Company's lead product candidate, ANEB-001, is a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. CB1 antagonists bind to the CB-1 receptor and thereby reverse the action of cannabinoids such as tetrahydrocannabinol (THC). It has completed Phase I trials.

Webull offers kinds of Anebulo Pharmaceuticals Inc stock information, including NASDAQ:ANEB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANEB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANEB stock methods without spending real money on the virtual paper trading platform.